Triptorelin Market size is anticipated to surpass USD 20 Billion by the end of 2035, expanding at a CAGR of 5% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of triptorelin was USD 10 Billion. The growing prevalence of central precocious puberty among children below the age of 8 or 9 is poised to dominate the market demand for triptorelin. Moreover, its frequency has been boosted since covid19 owing to growing stress among children. Hence, the use of triptorelin increased and is anticipated to boost even further owing to this factor. Triptorelin injection (Triptodur) for the treatment of central precocious puberty (CPP), a condition that causes puberty in children at an early stage and leads to faster bone growth and sexual traits development, in children aged 2 and older.
Inconsistency between biological sex and self-identified gender is a problem for transgender people. Hence, the use of triptorelin is also growing among transgender people for hormone replacement therapy. Hormone therapy is a common transitional treatment for transgender men and women. To promote virilization and decrease feminizing traits in transgender men, exogenous testosterone is administered. Anti-androgens are used as adjuncts to help suppress masculinizing characteristics in transgender women, and exogenous estrogen is used to help feminize patients. Moreover, triptorelin has the function of enabling control over ovarian function during ovarian stimulation cycles. It suppresses the LH peak that triggers ovulation, preventing spontaneous ovulation as a result. Additionally, it permits tracking of ovarian activity in people who have frozen embryo transfers or egg donation cycles and have an ovarian function. As a result, the endometrium could be in the best possible shape for embryo implantation.
Growth Drivers
According to the World Health Organization, about 38.4 million people worldwide were living with HIV in 2021. Hence, there has been going numerous trials to check the efficiency of triptorelin in HIV patient. However, even though this treatment is not widely used in HIV patients, owing to the ongoing research & development and huge investment from the pharmaceutical organization for the same, triptorelin treatment is estimated to be used to treat such patients during the forecast timeframe.
The second most frequently diagnosed cancer and the fifth highest cause of cancer death in males globally is considered to be prostate cancer, with a poised 1,414,000 new cancer cases and 375,304 deaths in 2020. The hormone testosterone is required for prostate cancer to develop. The testicles in men produce almost all of the testosterone. Triptorelin inhibits testosterone production in the testicles, lowering testosterone levels and slowing or halting the proliferation of cancer cells.
According to the World Health Organization, globally about 10% or 190 million women or girls of reproductive age are affected by endometriosis. It causes life-impacting pain in women during sexual intercourse, periods, bowel moment, and more. Hence, its treatment is necessary. Therefore, the use of triptorelin is growing since it has been proven effective with an acceptable safety profile. Also, since it has positive results on the reproductive part of the women, the problem in becoming could be diagnosed.
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~ 5% |
|
Base Year Market Size (2022) |
~ USD 10 Billion |
|
Forecast Year Market Size (2035) |
~ USD 20 Billion |
|
Regional Scope |
|
Drug Type (Triptorelin Pamoate, Triptorelin Acetate, Triptorelin Embonate)
Triptorelin market from the triptorelin embonate segment is expected to generate the highest revenue by the end of 2035. The growth of the segment can be attributed to the growing prevalence of prostate cancer since it is highly used in treating it. However, this is also used in treating endometriosis, and uterine fibroids. This is because, triptorelin embonate functions by restricting the release of hormones known as gonadotropins, which stimulate the testicles or ovaries.
Distribution Channel (Online Pharmacy, Hospital Pharmacy, others)
The hospital pharmacy segment in the triptorelin market is poised to have noteworthy growth over the forecast period. This segment expansion is expected to be influenced by rising hospital admission for gynecological disorders, or cancer. Also, these drugs are usually prescribed by a medical professional in the hospital, hence the attached pharmacies to the hospital make it convenient for the patient to find their prescribed drugs.
Our in-depth analysis of the global market includes the following segments:
|
Drug Type |
|
|
Application |
|
|
Distribution Channel |
|
North American Market Forecast
The triptorelin market in North America, amongst the market in all the other regions, is set to have the highest gain by the end of 2035, backed by growing demand for hormone therapy among men. Also, the number of transgender men in this region is also high, and are also demanding hormone therapy. About 2 million adults and youth identified themselves as transgender in the US in 2022.
APAC Market Statistics
The Asia Pacific triptorelin market is poised to have a significant growth over the forecast period. There has been growing awareness among people in this region regarding various treatments available in the market. This is why, the triptorelin market demand for triptorelin is set to grow in this region. Moreover, Asia Pacific the gaining popularity in medical treatment. Hong Kong, Singapore, South Korea, Japan, India and there are few which are considered to be the medical hub.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?